Intellia Therapeutics, Inc.
As of Oct 22, 2026, Intellia Therapeutics is in Stage 1, the basing phase, now in week 2 (since Oct 14, 2026). It closed at $11.16, 56.9% below its 52-week high and below its 200-day average, which is rising.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NTLA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NTLA among Biotechnology391st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …391 | NTLA | Stage 1 · wk 2 | 19 | −9.5% |
Intellia Therapeutics: quick answers
What stage is Intellia Therapeutics in?
As of Oct 22, 2026, Intellia Therapeutics (NTLA) is in Stage 1, the basing phase. It entered Stage 1 on Oct 14, 2026 and is in week 2. What the four stages mean
Is Intellia Therapeutics in an uptrend?
Not yet. Intellia Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 14.4% below its 200-day average, which is rising.
How far is Intellia Therapeutics from its 52-week high?
Intellia Therapeutics closed at $11.16 on Oct 22, 2026, 56.9% below its 52-week high of $25.89. Its 52-week low is $8.04.
How has Intellia Therapeutics performed over the past year?
As of Oct 22, 2026, Intellia Therapeutics is down 58.6% over the past year and up 21.2% so far in 2026.
Which sector and industry is Intellia Therapeutics in?
Intellia Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.